Related Experiment Video
Updated: Nov 3, 2025

Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice
Published on: January 13, 2012
Shear stress and ROS-responsive biomimetic micelles for atherosclerosis via ROS consumption
Meili Shen1, Hongli Li2, Shunyu Yao1
1Key Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun 130012, China.
Abstract:
Reactive oxygen species (ROS) are well-known important initiating factors required for atherosclerosis formation, which leads to endothelial dysfunction and plaque formation. Most of the existing antithrombotic therapies use ROS-responsive drug delivery systems, which have a certain therapeutic effect but cannot eliminate excess ROS. Therefore, the atherosclerosis cannot be treated from the source. Moreover, nanoparticles are easily cleared by the immune system during blood circulation, which is not conducive to long-term circulation. In this study, we developed an intelligent response system that could simultaneously respond to ROS and the shear stress microenvironment of atherosclerotic plaques. This system was formed by red blood cells (RBCs) and simvastatin-loaded micelles (SV MC). The micelles consisted of poly(glycidyl methacrylate)-polypropylene sulfide (PGED-PPS). The hydrophobic PPS could react with excess ROS to become hydrophilic, which forced the micelle rupture, resulting in drug release. Most importantly, PPS could also significantly deplete the ROS level, realizing the synergistic treatment of atherosclerosis with drugs and materials. The positively charged SV MC and negatively charged RBCs were self-assembled through electrostatic adsorption to obtain SV MC@RBCs. The SV MC@RBCs could respond to the high shear stress at the atherosclerotic plaque, and the shear stress induced SV MC desorption from the RBC surface. Using biomimetic methods to evade the SV MC@RBCs elimination by the immune system and to reduce the ROS plays a vital role in improving atherosclerosis treatment. The results of in vitro and in vivo experiments showed that SV MC@RBCs could effectively treat atherosclerosis. Moreover, not only does the SV MC@RBCs system avoid the risk of bleeding, but it also has excellent in vivo safety. The study results indicate that the SV MC@RBCs system is a promising therapeutic nanomedicine for treating ROS-related diseases.
Insights
This study introduces a novel nanomedicine system, SV MC@RBCs, that effectively treats atherosclerosis by simultaneously targeting reactive oxygen species (ROS) and plaque microenvironments. The system offers improved circulation and safety, addressing limitations of current therapies.
Area of Science:
- Biomaterials Science
- Nanomedicine
- Cardiovascular Research
Background:
- Reactive oxygen species (ROS) are key initiators of atherosclerosis, leading to endothelial dysfunction and plaque formation.
- Current antithrombotic therapies using ROS-responsive systems inadequately eliminate excess ROS, hindering source treatment.
- Nanoparticles face rapid clearance by the immune system, limiting their therapeutic efficacy in long-term circulation.
Purpose of the Study:
- To develop an intelligent nanomedicine system that responds to both ROS and the shear stress microenvironment of atherosclerotic plaques.
- To enhance atherosclerosis treatment by simultaneously depleting ROS and delivering therapeutic agents.
- To improve nanoparticle circulation time and reduce immune system clearance.
Main Methods:
- Development of simvastatin-loaded micelles (SV MC) composed of poly(glycidyl methacrylate)-polypropylene sulfide (PGED-PPS).
- Assembly of SV MC with red blood cells (RBCs) via electrostatic adsorption to form SV MC@RBCs.
- Evaluation of ROS-responsive micelle rupture and drug release, shear stress-induced desorption, immune evasion, and in vitro/in vivo therapeutic efficacy.
Main Results:
- The PGED-PPS micelles reacted with ROS, leading to micelle rupture and drug release, while also depleting ROS levels.
- SV MC@RBCs demonstrated responsiveness to shear stress, inducing micelle desorption from the RBC surface.
- In vitro and in vivo studies confirmed effective atherosclerosis treatment, improved circulation, and excellent safety profile without bleeding risks.
Conclusions:
- The SV MC@RBCs system offers a synergistic approach to atherosclerosis treatment by combining drug delivery with ROS scavenging.
- Biomimetic design enhances circulation time and reduces immune clearance, overcoming limitations of conventional nanoparticles.
- SV MC@RBCs represent a promising nanomedicine for treating ROS-related diseases, including atherosclerosis, with enhanced efficacy and safety.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Inflammation

